AIMS: Validate the application for iPad (Apple, California, USA) “Teste seu Cérebro” as well as establish cutoff point between normal seniors and Mild Neurocognitive Impairment.METHODS: In a prospective cross-sectional study, elderly subjects who attended the neuropsychology clinic of a tertiary health hospital in the southern region of Brazil and the community in general underwent cognitive assessment using two instruments: the Montreal Cognitive Assessment (Gold Standard Test) and the “Teste seu Cérebro”. These results served as a parameter to validate the said application from a diagnostic test and to establish the cutoff point between normal elderly and mild cognitive impairment; the following statistical measures were determined: sensitivity and specificity, internal consistency and reliability reached by the McDonald’s Omega coefficient and Pearson’s correlation coefficient, respectively. The average “Teste seu Cérebro” cutoff point to detect cases classified as mild neurocognitive impairment by the Montreal Cognitive Assessment was obtained through the ROC curve. Evaluations include functions such as memory, attention / orientation, fluency, language, and visuospatial skills. RESULTS: The sample consisted of 104 participants with mean age of 70.3 (standard deviation = 6.6), with a minimum age of 60 and a maximum of 87 years. An acceptable reliability was achieved for the “Teste seu Cérebro” application by analyzing the internal consistency. In the comparison between the general scores of the two instruments (Teste seu Cérebro and Montreal Cognitive Assessment), where the result showed a statistically significant correlation, positive and classified as moderate. The cutoff point of the “Teste seu Cérebro” scores that best discriminated patients with mild neurocognitive impairment diagnosed by the Montreal Cognitive Assessment was 89.5%, that is, scores below or equal to that percentage reached higher sensitivity and specificity for the instrument. No influence of sociodemographic variables such as sex, age and schooling were identified on the linearity relationship between the “Teste seu Cérebro” and Montreal Cognitive Assessment instruments. CONCLUSIONS: The results suggest that the “Teste seu Cérebro” instrument can be safely used to identify early and accurately the presence of Mild Neurocognitive Impairment in the elderly population. New studies will be directed to the validation of the instrument “Teste seu Cérebro” in the identification of other types of cognitive disorders, in addition to Mild Neurocognitive Impairment.
Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning
